The U.S. Food and Drug Administration (FDA) has cleared South Korean AI developer Vuno's brain quantification software Vuno Med-DeepBrain.
The software produces volumetric data on more than 100 brain regions through brain parcellation and provides cortical thickness and white matter hyperintensity measures. Vuno Med-DeepBrain then compares these results to those of healthy controls and produces an atrophy percentage.
The company hopes the software will help clinicians detect mild cognitive impairment or dementia earlier, it said.
